TBPK 2018 – Presentations

Tuesday, 23 October 2018

 Session 1: Pharmacokinetics and pharmacodynamics of new TB drugs
Chairs: Rob Aarnoutse & Jan-Willem Alfenaar
 New developments in pediatric TB treatment
Anneke Hesseling
Desmond Tutu Tuberculosis Centre, South Africa
(Not yet available)
 Abstract-driven presentations
 CPK/PD Support for a Phase 1 Study of TBA-7371
Jerry Nedelman, PhD
 Bedaquiline appears to antagonize its own main metabolite’s QTcF interval
prolonging effect
Lénaïg Tanneau, PhD
 Translational pharmacokinetic modelling & simulation of an experimental long-acting injectable formulation of bedaquiline
An Vermeulen, PhD
 Preclinical and Clinical Pharmacokinetics and Pharmacodynamics Analysis of Delamanid
Suresh Mallikaarjun, PHD, FCP
 Session 2: Pharmacokinetics and pharmacodynamics of approved TB drugs
Chairs: Geraint Davies & Helen McIlleron
 Abstract-driven presentations
 Higher rifampicin and isoniazid concentrations in epithelial lining fluid are associated with improved response to treatment in pulmonary TB
Andrew McCallum, MBChB
 Rifampicin, isoniazid and pyrazinamide exposures in children with DS-TB on
WHO-recommended FDCs in the SHINE trial
Helen McIlleron, MBChB, PhD
(Not yet available)
 Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention
Anthony Podany, PharmD
 Fluoroquinolones in the treatment of multidrug-resistant tuberculosis: experience from three US TB treatment centers
Charles Peloquin, PharmD
 Clofazimine pharmacokinetics in South African patients with drug-resistant tuberculosis
Sean Wasserman, MBChB, MMed
 Pharmacokinetic-Pharmacodynamic Target Attainment Analysis of Cycloserine in TB Patients
Charles Peloquin, PharmD
 Session 3: Population pharmacokinetics and pharmacokinetic-pharmacodynamic modeling
 Chairs: Jerry Nedelman & Eric Nuermberger
 Treatment of Multi-Drug Resistant TB
Bob Horsburgh
 Abstract-driven presentations
 High peak rifampicin concentrations accelerate the slow phase of bacterial elimination in tuberculosis patients
Antal Martinecz
 The Clinical value of Model-based Therapeutic Drug Monitoring in Tuberculosis Treatment – Optimized Target for Rifampicin
Ulrika Simonsson
(Not yet available)
 Model-based meta-analysis of rifampicin exposure and mortality in phase II
tuberculosis meningitis trials
Elin M Svensson
 Session 4: Drug development and optimization: approaches and tools
Chairs: Charles Peloquin & Kelly Dooley
 Abstract-driven presentations
 Clinical Validation of Intracellular Pharmacodynamic (PDi) based modelling for the prediction of Fluoroquinolone activity against TB
Ghaith Aljayyoussi, PhD
 Pharmacodynamic Correlates of Linezolid Activity and Toxicity in a Mouse TB Model
Kristina Bigelow, MS
 Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis
Elizabeth Tucker, MD
 Protein binding of rifampicin is not saturated when using high-dose rifampicin
Carlijn Litjens, MSc
 Using Mycobacterium tuberculosis single nucleotide polymorphisms to predict fluoroquinolone treatment response
Timothy Rodwell, MD PhD MPH